Special Issue "Treatments for Non-Small Cell Lung Cancer: The Multiple Options for Precision Medicine"

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editors

Prof. Dr. Jaafar Bennouna
E-Mail Website
Guest Editor
Medical Oncology Department, Hospitalier Universitaire De Nantes, Nantes, France
Interests: lung cancer; gastro-intestinal cancer; phase 1 trials; immunotherapy; targeted therapy
Dr. Elvire Pons-Tostivint
E-Mail Website
Guest Editor
Medical Oncology Department, University Hospital of Nantes, Nantes, France
Interests: lung cancer; clinical trials; tumor biology; targeted therapy; antibody-drug conjugates; immunotherapy; blood biomarkers

Special Issue Information

Dear Colleagues,

Lung cancer is one of the most aggressive cancers, with 1,796,1442 estimated deaths in 2020 worldwide. During the same time, 2,206,771 lung cancers were diagnosed, the majority of them with advanced disease. A multidisciplinary approach, supported by a broad therapeutic armamentarium including surgery, radiotherapy, and systemic treatments contributed to the recent advances that we have seen the past few years. Progress will also come through new techniques for the early detection of lung cancer (e.g., low-dose CT-scan). 

Overall, the discovery of new anticancer drugs was prompted in part by the identification of predictive biomarkers, but has also been fostered by innovative designs (master protocols, umbrella and basket trials) for early-phase clinical trials. We can affirm that lung cancers are one of the best examples of what precision medicine can do.

In this Special Issue, we wish to collect original research and review articles addressing all innovations dedicated to lung cancers, screening to detect early stages, treatments for localized or oligometastatic disease, and certainly biomarkers, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates.

Prof. Dr. Jaafar Bennouna
Dr. Elvire Pons-Tostivint
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • immunotherapy
  • targeted therapies
  • antibody–drug conjugates
  • biomarkers
  • screening
  • neo-adjuvant treatment
  • loco-regional treatments

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Clinical Implications of “Atypia” on Biopsy: Possible Precursor to Lung Cancer?
Curr. Oncol. 2021, 28(4), 2516-2522; https://doi.org/10.3390/curroncol28040228 - 06 Jul 2021
Viewed by 438
Abstract
Background: It is common for biopsies of concerning pulmonary nodules to result in cytologic “atypia” on biopsy, which may represent a benign response or a false negative finding. This investigation evaluated time to diagnosis and factors which may predict an ultimate diagnosis of [...] Read more.
Background: It is common for biopsies of concerning pulmonary nodules to result in cytologic “atypia” on biopsy, which may represent a benign response or a false negative finding. This investigation evaluated time to diagnosis and factors which may predict an ultimate diagnosis of lung cancer in these patients with atypia cytology on lung nodule biopsy. Methods: This retrospective study included patients of the Stony Brook Lung Cancer Evaluation Center who had a biopsy baseline diagnosis of atypia between 2010 and 2020 and were either diagnosed with cancer or remained disease free by the end of the observation period. Cox Proportional Hazard (CPH) Models were used to assess factor effects on outcomes. Results: Among 106 patients with an initial diagnosis of atypia, 80 (75%) were diagnosed with lung cancer. Of those, over three-quarters were diagnosed within 6 months. The CPH models indicated that PET positivity (SUV ≥ 2.5) (HR = 1.74 (1.03, 2.94)), nodule size > 3.5 cm (HR = 2.83, 95% CI (1.47, 5.45)) and the presence of mixed ground glass opacities (HR = 2.15 (1.05, 4.43)) significantly increased risk of lung cancer. Conclusion: Given the high conversion rate to cancer within 6 months, at least tight monitoring, if not repeat biopsy may be warranted during this time period for patients diagnosed with atypia. Full article
Show Figures

Figure 1

Back to TopTop